UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Patient characteristics and triggers eliciting refractory chronic cough

The World Allergy Organization journal, 2020-08, Vol.13 (8), p.100209, Article 100209

2020

Volltextzugriff (PDF)

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

The World Allergy Organization journal, 2020-08, Vol.13 (8), p.100203, Article 100203

2020

Volltextzugriff (PDF)

29 Ivacaftor treatment is associated with a decline in symptoms of extra-oesophageal reflux in patients with cystic fibrosis and the G551D mutation

Journal of cystic fibrosis, 2016-06, Vol.15, p.S58-S59

2016

Volltextzugriff (PDF)

Characterization of a Hek293 Cell Line Permanently Co-Expressing the Cough Receptors Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (Trpa1 and Trpv1)

Pulmonary pharmacology & therapeutics, 2011, Vol.24 (3), p.e8-e8

2011

Volltextzugriff (PDF)

159 Fundoplication for reflux induced cough in cystic fibrosis

Journal of cystic fibrosis, 2007, Vol.6, p.S39-S39

2007

Volltextzugriff (PDF)

Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD

Biomedical signal processing and control, 2021-01, Vol.63, p.102205, Article 102205

2021

Volltextzugriff (PDF)

Tackling the heart sink symptom: ERS guidelines on chronic cough

Breathe (Lausanne, Switzerland), 2004-12, Vol.1 (2), p.89-90

Morice, A.H.

2004

Volltextzugriff (PDF)

Chronic cough: diagnosis, treatment and psychological consequences

Breathe (Lausanne, Switzerland), 2006-12, Vol.3 (2), p.164-174

Morice, A.H.

2006

Volltextzugriff (PDF)

A28 Lung ventilation scintigraphy used to assess aerosol nebulizer deposition and repeatability in CF

Nuclear medicine communications, 2006-07, Vol.27 (7), p.A6-A7

2006

Volltextzugriff (PDF)

Therapeutic equivalence of a novel budesonide/formoterol pMDI versus budesonide/formoterol turbuhaler® in adolescents and adults with asthma

Journal of allergy and clinical immunology, 2005-02, Vol.115 (2), p.S2-S2

2005

Volltextzugriff (PDF)

The novel budesonide/formoterol pMDI is therapeutically equivalent to budesonide/formoterol Turbuhaler® in children with asthma

Journal of allergy and clinical immunology, 2005-02, Vol.115 (2), p.S209-S209

2005

Volltextzugriff (PDF)

Performance Requirements for Cough Classifiers in Real-World Applications

2020 28th European Signal Processing Conference (EUSIPCO), 2021, p.96-100

2021

Volltextzugriff (PDF)

Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol turbuhaler® in adolescents and adults with asthma

Journal of allergy and clinical immunology, 2005-02, Vol.115 (2), p.S3-S3

2005

Volltextzugriff (PDF)

The ETAAntagonist CI-1020 Inhibits Hypoxic Pulmonary Vasoconstriction in Small Isolated Rat Pulmonary Arteries

Pulmonary pharmacology & therapeutics, 1998-04, Vol.11 (2-3), p.177-181

1998

Volltextzugriff (PDF)

The Effect of the ETAReceptor Antagonist (CI-1020) in Rats with Established Hypoxic Pulmonary Hypertension

Pulmonary pharmacology & therapeutics, 1998-04, Vol.11 (2-3), p.173-176

1998

Volltextzugriff (PDF)

Genetically mediated variation in angiotensin-converting enzyme expression and vascular reactivity in human resistance vessels

Journal of the American College of Cardiology, 1998-02, Vol.31, p.462-462

1998

Volltextzugriff (PDF)

Software

The Lancet (British edition), 1987-10, Vol.330 (8563), p.830

1987

Volltextzugriff (PDF)

TREATMENT OF SYSTEMIC CAPILLARY LEAK SYNDROME

The Lancet (British edition), 1988-12, Vol.332 (8626-8627), p.1496-1496

1988

Volltextzugriff (PDF)

Electrical impedance tomographic spectroscopy in the detection of increased lung water in heart failure

Proceedings of 18th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 1996, Vol.2, p.778-779 vol.2

1996

Volltextzugriff (PDF)

45 A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients

Journal of cystic fibrosis, 2014-06, Vol.13, p.S58-S58

2014

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(18)
Tagungsberichte
(2)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Patient characteristics and triggers eliciting refractory chronic cough

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

29 Ivacaftor treatment is associated with a decline in symptoms of extra-oesophageal reflux in patients with cystic fibrosis and the G551D mutation

Characterization of a Hek293 Cell Line Permanently Co-Expressing the Cough Receptors Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (Trpa1 and Trpv1)

159 Fundoplication for reflux induced cough in cystic fibrosis

Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD

Tackling the heart sink symptom: ERS guidelines on chronic cough

Chronic cough: diagnosis, treatment and psychological consequences

A28 Lung ventilation scintigraphy used to assess aerosol nebulizer deposition and repeatability in CF

Therapeutic equivalence of a novel budesonide/formoterol pMDI versus budesonide/formoterol turbuhaler® in adolescents and adults with asthma

The novel budesonide/formoterol pMDI is therapeutically equivalent to budesonide/formoterol Turbuhaler® in children with asthma

Performance Requirements for Cough Classifiers in Real-World Applications

Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol turbuhaler® in adolescents and adults with asthma

The ETAAntagonist CI-1020 Inhibits Hypoxic Pulmonary Vasoconstriction in Small Isolated Rat Pulmonary Arteries

The Effect of the ETAReceptor Antagonist (CI-1020) in Rats with Established Hypoxic Pulmonary Hypertension

Genetically mediated variation in angiotensin-converting enzyme expression and vascular reactivity in human resistance vessels

Software

TREATMENT OF SYSTEMIC CAPILLARY LEAK SYNDROME

Electrical impedance tomographic spectroscopy in the detection of increased lung water in heart failure

45 A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients

Aktive Filter

Suchergebnisse filtern